1097 related articles for article (PubMed ID: 25678098)
1. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Filippatos G; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Kim SY; Nowack C; Palombo G; Kolkhof P; Kimmeskamp-Kirschbaum N; Pieper A; Pitt B
Eur Heart J; 2016 Jul; 37(27):2105-14. PubMed ID: 27130705
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Sato N; Ajioka M; Yamada T; Kato M; Myoishi M; Yamada T; Kim SY; Nowack C; Kolkhof P; Shiga T;
Circ J; 2016 Apr; 80(5):1113-22. PubMed ID: 27074824
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
[TBL] [Abstract][Full Text] [Related]
5. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
7. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Pitt B; Filippatos G; Gheorghiade M; Kober L; Krum H; Ponikowski P; Nowack C; Kolkhof P; Kim SY; Zannad F
Eur J Heart Fail; 2012 Jun; 14(6):668-75. PubMed ID: 22562554
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Pitt B; Kober L; Ponikowski P; Gheorghiade M; Filippatos G; Krum H; Nowack C; Kolkhof P; Kim SY; Zannad F
Eur Heart J; 2013 Aug; 34(31):2453-63. PubMed ID: 23713082
[TBL] [Abstract][Full Text] [Related]
10. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
[TBL] [Abstract][Full Text] [Related]
11. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
13. Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes.
Dey S; Garg J; Wang A; Holzner E; Frishman WH; Aronow WS
Cardiol Rev; 2024 May-Jun 01; 32(3):285-288. PubMed ID: 36946916
[TBL] [Abstract][Full Text] [Related]
14. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
[TBL] [Abstract][Full Text] [Related]
17. Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2022 Oct; 16(10):102638. PubMed ID: 36223666
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
[TBL] [Abstract][Full Text] [Related]
19. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
20. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]